

**Novel Oncology Therapeutics: Targeting Hope
On Demand Course**

Premier Sponsor



AGENDA		
Session Duration	Topic	Presenter(s)
90 minutes	<p>Lecture Series – The Expanding Clinical Role of Cancer Immunotherapy</p> <ul style="list-style-type: none"> • Understand the therapeutic application, clinical indication, common treatment schedules, and toxicity profiles of adoptive T cell therapy • Recognize the clinical application and immunologic response assessment of checkpoint blockade therapy, as well as understand mechanisms of resistance and management of toxicities associated with checkpoint blockade • Describe the clinical application CAR T-cell therapy for solid tumors and understand the potential benefits and challenges of use in veterinary oncology. • Recognize clinical utility of repurposed medications to modulate tumor and tumor microenvironment interactions • Incorporate information discussed in this session into your clinical practice and client discussions 	<p><i>Dr. Brooke Fowler, Dr. Nicola Mason, Dr. Dan Regan</i></p>
60 minutes	<p>Interactive Discussion – Cancer Immunotherapy</p> <ul style="list-style-type: none"> • Understand the therapeutic application, clinical indication, common treatment schedules, and toxicity profiles of adoptive T cell therapy. • Recognize the clinical application and immunologic response assessment of checkpoint blockade therapy, as well as understand mechanisms of resistance and management of toxicities associated with checkpoint blockade • Describe the clinical application CAR T-cell therapy for solid tumors and understand the potential benefits and challenges of use in veterinary oncology. • Recognize clinical utility of repurposed medications to modulate tumor and tumor microenvironment interactions • Incorporate information discussed in this session into your clinical practice and client discussions 	<p><i>Dr. Brooke Fowler, Dr. Nicola Mason, Dr. Dan Regan</i></p> <p><i>Moderator: Dr. Joelle Fenger</i></p>

**Novel Oncology Therapeutics: Targeting Hope
On Demand Course**

Premier Sponsor



AGENDA		
Session Duration	Topic	Presenter(s)
60 minutes	<p>Lecture Series – Targeted Therapies: Pre-Clinical and Pharmacologic Considerations</p> <ul style="list-style-type: none"> Describe the methodology and model systems utilized to assess efficacy, tolerability, and dosing schedules for targeted therapeutics Recognize gaps in our knowledge regarding optimal dose and schedule for targeted therapeutics in veterinary cancer patients Understand limitations of extrapolating preclinical safety and tolerability data of targeted therapies to veterinary patients with cancer Understand the difference between FDA-approved and 503A and 503B compounded products Incorporate information discussed in this session into your clinical practice and client discussions 	<p><i>Dr. Luke Wittenburg, Dr. Heather Gardner, Dr. Lauren Forsythe</i></p>
60 minutes	<p>Interactive Discussion – Targeted Therapies: Pre-Clinical and Pharmacologic Considerations</p> <ul style="list-style-type: none"> Describe the methodology and model systems utilized to assess efficacy, tolerability, and dosing schedules for targeted therapeutics Recognize gaps in our knowledge regarding optimal dose and schedule for targeted therapeutics in veterinary cancer patients Understand limitations of extrapolating preclinical safety and tolerability data of targeted therapies to veterinary patients with cancer Understand the difference between FDA-approved and 503A and 503B compounded products Incorporate information discussed in this session into your clinical practice and client discussions 	<p><i>Dr. Luke Wittenburg, Dr. Heather Gardner, Dr. Lauren Forsythe</i></p> <p><i>Moderator: Dr. Sue Lana</i></p>

**Novel Oncology Therapeutics: Targeting Hope
On Demand Course**

Premier Sponsor



AGENDA		
Session Duration	Topic	Presenter(s)
30 minutes	<p>Immune Checkpoint Inhibitors: Oh, the Places (We Hope!) You'll Go – Presented by Merck</p> <ul style="list-style-type: none"> Understand the pros and cons of several potential biomarkers for successful use of immune checkpoint inhibition therapy and review what we currently know about these biomarkers in veterinary medicine. Gain familiarity with the indications, administration, and safety profile of gilvetmab. 	<i>Dr. Laura Greene</i>
90 minutes	<p>Lecture Series – Targeted Therapies: Clinical Applications, Combinations and Clinicians' Experiences</p> <ul style="list-style-type: none"> Become familiar with newer targeted therapies available in veterinary oncology Recognize gaps in our knowledge regarding optimal clinical application of targeted therapies in canine and feline cancers Describe the dosing strategies and potential toxicity profiles for protocols combining targeted therapies Incorporate information discussed in this session into your clinical practice and client discussions 	<i>Dr. Bridget Urie, Dr. Marilia Takada, Dr. Joelle Fenger, Dr. Mark Byrum</i>
60 minutes	<p>Interactive Discussion – Targeted Therapies: Clinical Applications, Combinations and Clinicians' Experiences</p> <ul style="list-style-type: none"> Become familiar with newer targeted therapies available in veterinary oncology Recognize gaps in our knowledge regarding optimal clinical application of targeted therapies in canine and feline cancers Describe the dosing strategies and potential toxicity profiles for protocols combining targeted therapies Incorporate information discussed in this session into your clinical practice and client discussions 	<p><i>Dr. Bridget Urie, Dr. Marilia Takada, Dr. Joelle Fenger, Dr. Mark Byrum</i></p> <p><i>Moderator: Dr. Jenna Burton</i></p>